Lupus & antiphospholipid syndrome
Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: A systematic review
Authors' conclusion
Adverse effects are common on this treatment, and there is potential for serious adverse events.
Study context
- Population
- Adults with SLE; Embase, MEDLINE and Web of Science searched through June 20257 studies (2 RCTs, 5 non-randomised)
- Participants
- 185 adults
- Comparison
- Combination RTX then belimumab therapy
- Outcome
- Safety and tolerability of combination RTX and belimumab therapy
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Treatment-emergent adverse events (TEAEs)
| Group | Value | Discontinued treatment due to treatment-emergent adverse events (TEAEs) |
|---|---|---|
| RTX + belimumab | 7 events | 7 |
RTX + belimumab
Value7 events
Discontinued treatment due to treatment-emergent adverse events (TEAEs)7
Safety
| Outcome | Values |
|---|---|
| Discontinuation due to TEAEs | RTX + belimumab 7 events |
Original publication
Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: A systematic review. Lupus. Published 29 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →